ProCE Banner Activity

CME

Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes

Video

Watch this on-demand webcast from a June 2023 live webinar featuring Michael R. Bishop, MD; Julie M. Vose, MD; and Kathleen Dorritie, MD, on the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinal practice.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 23, 2023

Expiration: June 22, 2024

No longer available for credit.

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Kathleen Dorritie

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Julie M Vose

Julie M Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recall the scientific rationale, key evidence, and expanding role of current and emerging CAR T-cell therapies in CLL/SLL, DLBCL, FL, and MCL

  • Plan individualized therapeutic strategies to optimize integration of CAR T-cell therapies for patients with hematologic malignancies including patient selection, referral to specialized CAR T-cell treatment centers, patient care coordination, and pre/post treatment support

  • Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies in patients with hematologic malignancies

  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies for appropriate and inclusive patient enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Primary Author

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD: consultant/advisor/speaker: CRISPR Therapeutics, Kite/Gilead, Novartis; researcher: Autolus.

Contributing Author

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Kathleen Dorritie, MD: consultant/advisor/speaker: Bristol Myers Squibb; researcher (paid to institution): Juno/Bristol Myers Squibb, Kite/Gilead, Genmab, Janssen.

Julie M Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 23, 2023, through June 22, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material  for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.